stars 1 stars 2 stars 3

Amogen Pharma is India's leading recombinant peptide and biosimilar company, developing and manufacturing GLP-1 APIs including semaglutide and liraglutide via proprietary Saccharomyces cerevisiae fermentation technology. Founded in 2020 and headquartered in Hyderabad, India, Amogen operates Plant 1 — India's largest dedicated GLP-1 API facility with 980 Kg API capacity. Our pipeline includes semaglutide (Phase 1, Q4 2026), liraglutide, tirzepatide, insulin degludec, insulin aspart and Insulin Degludec + Liraglutide — covering a cumulative market of $80B+. We partner globally for API supply, FDF licensing and long-term commercial agreements across India, GCC, ASEAN, LATAM,Canada, EU and North America.

Amogen Pharma Questions

Manpreet Singh is the President Business Development of Amogen Pharma.

17 people are employed at Amogen Pharma.

Amogen Pharma is based in Hyderabad, Telangana.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users